[go: up one dir, main page]

PE20050432A1 - Derivados 2-sulfonil-decahidroisoquinolina como inhibidores de metaloproteinasas de matriz - Google Patents

Derivados 2-sulfonil-decahidroisoquinolina como inhibidores de metaloproteinasas de matriz

Info

Publication number
PE20050432A1
PE20050432A1 PE2004000918A PE2004000918A PE20050432A1 PE 20050432 A1 PE20050432 A1 PE 20050432A1 PE 2004000918 A PE2004000918 A PE 2004000918A PE 2004000918 A PE2004000918 A PE 2004000918A PE 20050432 A1 PE20050432 A1 PE 20050432A1
Authority
PE
Peru
Prior art keywords
sulfonil
alkyl
decahydroisoquinoline
sulfonyl
inhibitors
Prior art date
Application number
PE2004000918A
Other languages
English (en)
Inventor
Manfred Schudok
Hans Matter
Armin Hofmeister
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of PE20050432A1 publication Critical patent/PE20050432A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A DERIVADOS DE IMINOACIDOS BICICLICOS DE FORMULA I DONDE A ES ALQUILENO (C0-C4), B, D Y E SON ALQUILENO (C0-C4) O EL RADICAL -B1-B2-B3- EN B1 ES -(CH2)n- DONDE n ES 0-2; B3 ES -(CH2)m- DONDE m ES 0-2 CON LA CONDICION DE QUE LA SUMA DE n Y m ES 0-2 Y B2 ES -C(O)-, ALQUENILENO (C2-C4), -N(R6)- EN EL QUE R6 ES H, METILO, ETILO; R1 A R5 SON H, ALQUILO C1-C6, ALQUINILO C2-C6, O-R8 DONDE R8 ES H, ALQUILO C1-C6, ENTRE OTROS; ANILLO 1 A 3 INDEPENDIENTE UNOS DE OTROS SON UN ENLACE COVALENTE, FENILO O NAFTILO, ANILLO HET DE 4 A 15 MIEMBROS DONDE EL ANILLO HET ES UN RADICAL DE LA SERIE ACRIDINILO, AZEPINILO, AZETIDINILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 2-(4'-NITROBIFENIL-4-SULFONIL)-DECAHIDROISOQUINOLINO-1-(N-HIDROXI)CARBOXAMIDA, ACIDO 2-(4'-CLOROBIFENIL-4-SULFONIL)-DECAHIDROISOQUINOLINO-1-CARBOXILICO, 2-(4'-CLOROBIFENIL-4-SULFONIL)DECAHIDROISOQUINOLINO-1-(N-HIDROXI)CARBOXAMIDA, TRIFLUOROACETATO DE 2-(6-FENOXIPIRIDIN-6-SULFONIL)DECAHIDROISOQUINOLINO-1-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE METALOPROTEINASAS DE MATRIZ Y SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS
PE2004000918A 2003-09-27 2004-09-21 Derivados 2-sulfonil-decahidroisoquinolina como inhibidores de metaloproteinasas de matriz PE20050432A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10344936A DE10344936A1 (de) 2003-09-27 2003-09-27 Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen

Publications (1)

Publication Number Publication Date
PE20050432A1 true PE20050432A1 (es) 2005-07-21

Family

ID=34353126

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000918A PE20050432A1 (es) 2003-09-27 2004-09-21 Derivados 2-sulfonil-decahidroisoquinolina como inhibidores de metaloproteinasas de matriz

Country Status (24)

Country Link
EP (1) EP1670766B1 (es)
JP (1) JP4861179B2 (es)
KR (1) KR20060086367A (es)
CN (1) CN1856478B (es)
AR (1) AR046165A1 (es)
AT (1) ATE550327T1 (es)
AU (1) AU2004275937A1 (es)
BR (1) BRPI0414594A (es)
CA (1) CA2539731A1 (es)
DE (1) DE10344936A1 (es)
IL (1) IL174040A0 (es)
MA (1) MA28075A1 (es)
ME (1) MEP33008A (es)
MX (1) MXPA06002927A (es)
MY (1) MY139830A (es)
NO (1) NO20061837L (es)
NZ (1) NZ546158A (es)
PE (1) PE20050432A1 (es)
RS (1) RS20060194A (es)
RU (1) RU2335494C2 (es)
TW (1) TW200520755A (es)
UY (1) UY28539A1 (es)
WO (1) WO2005030728A1 (es)
ZA (1) ZA200601501B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln
DE102004031850A1 (de) * 2004-06-30 2006-01-26 Sanofi-Aventis Deutschland Gmbh Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE102005002500A1 (de) * 2005-01-19 2006-07-27 Sanofi-Aventis Deutschland Gmbh Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
DE102005015040A1 (de) * 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
US8790714B2 (en) 2007-08-03 2014-07-29 Nucitec, S.A. De C.V. Compositions and methods for treatment and prevention of osteoarthritis
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201303B (es) * 1990-07-05 1993-03-01 Hoffmann La Roche
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
FR2701480B1 (fr) * 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
RU2164914C2 (ru) * 1995-11-13 2001-04-10 Хехст Акциенгезелльшафт ЦИКЛИЧЕСКИЕ И ГЕТЕРОЦИКЛИЧЕСКИЕ N-ЗАМЕЩЕННЫЕ α-ИМИНОГИДРОКСАМОВЫЕ И КАРБОНОВЫЕ КИСЛОТЫ
NZ334253A (en) * 1996-08-28 2000-11-24 Procter & Gamble N-hydroxy 1-[(4-methoxyphenyl)sulfonyl]-4-benzyloxycarbonyl-piperazine 2-carboxamide and derivatives thereof for treating musculoskeletal disease or cachexia
PL334846A1 (en) * 1997-01-23 2000-03-27 Hoffmann La Roche Sulphamidic inhibitors of metaloproteases
DE19719817A1 (de) * 1997-05-13 1998-11-19 Hoechst Ag Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren
DE10300015A1 (de) * 2003-01-03 2004-07-15 Aventis Pharma Deutschland Gmbh Iminosäurederivate als Inhibitoren von Matrix-Metallproteinasen
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln

Also Published As

Publication number Publication date
NZ546158A (en) 2008-11-28
CA2539731A1 (en) 2005-04-07
KR20060086367A (ko) 2006-07-31
RU2006114352A (ru) 2006-08-27
WO2005030728A1 (de) 2005-04-07
MA28075A1 (fr) 2006-08-01
EP1670766B1 (de) 2012-03-21
AU2004275937A1 (en) 2005-04-07
RS20060194A (sr) 2008-08-07
EP1670766A1 (de) 2006-06-21
AR046165A1 (es) 2005-11-30
CN1856478B (zh) 2010-05-26
DE10344936A1 (de) 2005-04-21
MXPA06002927A (es) 2006-06-14
RU2335494C2 (ru) 2008-10-10
TW200520755A (en) 2005-07-01
JP4861179B2 (ja) 2012-01-25
CN1856478A (zh) 2006-11-01
ATE550327T1 (de) 2012-04-15
NO20061837L (no) 2006-06-01
IL174040A0 (en) 2006-08-01
MEP33008A (en) 2010-10-10
JP2007506690A (ja) 2007-03-22
ZA200601501B (en) 2007-04-25
MY139830A (en) 2009-10-30
BRPI0414594A (pt) 2006-11-07
UY28539A1 (es) 2005-04-29

Similar Documents

Publication Publication Date Title
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
PE20211911A1 (es) Compuestos heterociclicos como inmunomoduladores
PE20190705A1 (es) COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING
UY27918A1 (es) Derivados de benzodioxol
UY30326A1 (es) Derivados de cicloalquilaminoacidos
AR060749A1 (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
PA8523001A1 (es) Derivados de la 3-indolil-4-fenil-1h-pirrol-2,5-diona como inhibidores de glicogeno sintasa quinasa-3b
PE20160682A1 (es) Composiciones y metodos para modular los receptores x farnesoides
CO5690585A2 (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
MX9404749A (es) Heterociclos de fenilo como inhibidores de cox-2.
PE20091621A1 (es) Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen
AR072331A2 (es) Derivados de acido mandelico, formulacion farmaceutica, procesos para la preparacion de estos derivados, y compuestos intermediarios
PE20121695A1 (es) 5-alquinil-pirimidinas
UY32138A (es) Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
SV2004001548A (es) Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
AR047529A1 (es) Compuestos de quinolina sustituidos
CL2003002769A1 (es) Compuestos derivados de carboxamida de tiazolilpirrol; procedimiento para su preparacion; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores canabinoid
PA8576001A1 (es) "difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion , medicamentos que comprenden estos compuestos y su uso".
PE20080381A1 (es) Fungicidas derivados de azolilmetiloxiranos y productos que los contienen
NO20052976D0 (no) Fosfodiesterase-4-inhibitorer.
AR039601A1 (es) Derivados de nitrosodifenilamina y composiciones farmaceuticas que los comprenden como medicamentos que se pueden utilizar en el tratamiento de patologias que se caracterizan por estres oxidativo
CO5660289A2 (es) Derivados de 4-piridinilmetilsulfonamida como agentes fungicidas para proteccion de plantas
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
AR052972A1 (es) Derivados de carboxamidas como agentes contra hongos patogenos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed